Translation of Anticancer Efficacy From Nonclinical Models to the Clinic

DSpace/Manakin Repository

Translation of Anticancer Efficacy From Nonclinical Models to the Clinic

Citable link to this page

 

 
Title: Translation of Anticancer Efficacy From Nonclinical Models to the Clinic
Author: Stroh, M; Duda, D G; Takimoto, C H; Yamazaki, S; Vicini, P

Note: Order does not necessarily reflect citation order of authors.

Citation: Stroh, M, D G Duda, C H Takimoto, S Yamazaki, and P Vicini. 2014. “Translation of Anticancer Efficacy From Nonclinical Models to the Clinic.” CPT: Pharmacometrics & Systems Pharmacology 3 (8): e128. doi:10.1038/psp.2014.28. http://dx.doi.org/10.1038/psp.2014.28.
Full Text & Related Files:
Abstract: Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary modeling and simulation effort will strengthen the current oncology drug development paradigm.
Published Version: doi:10.1038/psp.2014.28
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150926/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987402
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters